The main differences concern the German assessment question, appropriate comparator therapy, patient populations, patient-relevant outcomes, evidence updates and national requirements such as epidemiology and treatment costs.
JCA-to-AMNOG translation map
The JCA-to-AMNOG translation determines which European evidence supports the German benefit assessment and where national additions or analyses remain necessary.
| JCA content | German AMNOG question | Typical national action |
|---|---|---|
| Assessment scope and PICO | Does the JCA evidence cover the German population and assessment question? | Map German populations and relevant JCA PICOs |
| Comparator scenarios | Does the evidence address the German appropriate comparator therapy? | Confirm the German comparator and identify evidence gaps |
| Health outcomes | Are the outcomes patient-relevant under German requirements? | Review endpoint acceptance and operationalisation |
| Relative effects | Are the analyses suitable for the German assessment? | Reanalyse or supplement evidence where required |
| Evidence cut-off | Is the evidence current when the AMNOG procedure starts? | Update searches, follow-up and relevant data cuts |
| References and methods | Can the referenced evidence be clearly identified and assessed? | Create precise reference mapping and documentation |
| National information | Which information is outside the clinical JCA scope? | Add German epidemiology, population and cost information |
JCA dossier and AMNOG dossier at a glance
What is a JCA dossier?
A JCA dossier is the pharmaceutical developer's clinical evidence submission for a Joint Clinical Assessment under the EU HTA framework. It provides the evidence used to assess relative clinical effects against one or more European PICO questions.
What is an AMNOG dossier?
An AMNOG dossier is the national evidence submission for Germany's early benefit assessment under AMNOG. It supports the assessment of added benefit by the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) and contains both clinical evidence and Germany-specific information.
Does the JCA dossier replace the AMNOG dossier?
No. The JCA dossier does not replace the German AMNOG dossier or the national assessment of added benefit. The AMNOG module structure remains in place after a Joint Clinical Assessment.
What is the main difference between the JCA dossier and AMNOG dossier?
The JCA dossier supports a European clinical assessment, while the AMNOG dossier supports a national German added-benefit assessment. The German submission therefore needs to answer national questions that are not fully covered by the European dossier.
What is the difference between the JCA dossier and the AMNOG dossier?
| JCA dossier | AMNOG dossier | |
|---|---|---|
| Purpose | European clinical evidence submission | German national benefit submission |
| Assessment level | European Union | Germany |
| Assessment question | One or more European PICOs | German assessment question |
| Comparator | Comparator scenarios from the European scope | Appropriate comparator therapy relevant to Germany |
| Clinical evidence | Central focus of the submission | Used for the German added-benefit assessment |
| Population | Population defined through the JCA scope | Population and potential subpopulations relevant to the G-BA |
| National epidemiology | Not the primary purpose | Required for the German target population |
| Treatment costs | Not part of the clinical assessment | Germany-specific requirement |
| Added-benefit decision | No | Basis for the national G-BA assessment |
| Reimbursement | No European reimbursement decision | Assessment feeds into the German reimbursement process |
Why does Germany still require national AMNOG content after a JCA?
- the appropriate comparator therapy relevant to the German assessment,
- German patient populations and potential subpopulations,
- national requirements for patient-relevant outcomes and analyses,
- updated clinical evidence where required,
- prevalence, incidence and the German target population,
- treatment costs for statutory health insurance,
- requirements for quality-assured use,
- and the national added-benefit claim.
The European JCA can therefore provide an important clinical evidence basis without determining the final German assessment.
For a detailed explanation of the German dossier structure, see The AMNOG dossier.
Which JCA dossier content can be reused in the AMNOG dossier?
- study descriptions and study-design information,
- clinical study results,
- evidence tables,
- endpoint analyses,
- methodological information,
- information on relative treatment effects,
- and relevant parts of the evidence identification process.
Reuse is not automatic. Five questions determine whether European content can support the German dossier:
- Population: Does the evidence represent the population assessed in Germany?
- Comparator: Does the evidence address the appropriate comparator therapy?
- Outcomes: Are the endpoints and their operationalisation suitable for the German assessment?
- Methods: Do the analyses meet the requirements relevant to the national assessment?
- Timing: Is the evidence sufficiently current when the AMNOG procedure starts?
Where these conditions are not met, additional national content, updated evidence or further analyses may be required.
Where can JCA and AMNOG requirements differ?
| Area | JCA | German AMNOG assessment |
|---|---|---|
| Assessment scope | European PICO questions | German assessment question |
| Comparator | One or more European comparator scenarios | Appropriate comparator therapy relevant to Germany |
| Population | Population defined through European scoping | German population and potential G-BA subpopulations |
| Outcomes | Outcomes included in the JCA scope | Patient relevance and analytical requirements remain nationally relevant |
| Evidence timing | Evidence available for the JCA | New data cuts, studies or searches may become relevant nationally |
| Epidemiology and costs | Outside the core clinical assessment | Germany-specific dossier requirements |
| Decision | Assessment of relative clinical effects | National assessment of added benefit |
These differences determine whether European evidence can be used directly, requires adaptation or needs to be supplemented for Germany.
For a deeper analysis of comparator therapy, endpoints, evidence updates and timing, see Five theses on the Delta-Dossier.
What is a Delta-Dossier?
- identifying reusable JCA content,
- mapping European evidence to the German assessment question,
- adding Germany-specific information,
- updating evidence,
- supplementing or adapting analyses,
- and creating precise references between European and national content.
The practical implications extend beyond dossier writing. PICO scoping, comparator strategy, endpoint selection and evidence planning can determine whether European evidence will later be usable in Germany.
Which AMNOG modules remain relevant after a JCA?
The existing AMNOG module structure remains relevant after a Joint Clinical Assessment.
In particular, Module 3 contains Germany-specific information such as the target population, epidemiology, treatment costs and requirements for quality-assured use. Module 4 has the strongest interface with the clinical evidence contained in the JCA dossier but may still require national analyses, evidence updates and an added-benefit derivation for Germany.
A detailed description of all five modules is available in The AMNOG dossier.
JCA dossier, AMNOG dossier and the German assessment process
- JCA scope and dossier: European PICOs define the clinical assessment questions and the manufacturer submits the relevant evidence.
- JCA assessment: European assessors evaluate the submitted clinical evidence.
- JCA-to-AMNOG translation: The manufacturer identifies reusable evidence and Germany-specific gaps.
- AMNOG dossier and benefit assessment: The national submission addresses the German assessment question and supports the G-BA assessment of added benefit.
The JCA dossier is therefore an important evidence source for Germany, but it is not the final German submission.
Explore the AMNOG and JCA guides
For the individual components of the German pathway:
- The AMNOG process in Germany explains the procedural steps, institutions, timeline and reimbursement pathway.
- AMNOG legislation in Germany covers Section 35a SGB V, the AM-NutzenV and the legal framework.
- The AMNOG dossier explains the five dossier modules and German evidence requirements.
- Five theses on the Delta-Dossier analyses the practical JCA-to-AMNOG interface, including comparator therapy, endpoints, evidence updates, timing and lessons from the first practical cases.
Frequently asked questions about JCA and AMNOG dossiers
Does the JCA dossier replace the AMNOG dossier?
No. The JCA dossier provides evidence for the European clinical assessment, while Germany continues to require a national AMNOG submission and added-benefit assessment.
What is the difference between a JCA dossier and a JCA report?
The pharmaceutical developer submits the JCA dossier, while the JCA report is produced through the European assessment process. The dossier is an input into the assessment; the report records the assessment findings.
Can JCA dossier content be reused in the AMNOG dossier?
Yes, where the content addresses the German assessment question and meets the relevant national requirements. Additional analyses, evidence updates or national information may still be required.
Which content remains specifically relevant for Germany?
The German comparator, national populations, national assessment requirements, epidemiology, treatment costs, quality-assured use and the national added-benefit claim remain relevant for the AMNOG dossier.
Is there an official Delta-Dossier template?
No. Delta-Dossier is a working term. The formal German submission continues to use the AMNOG module structure.